Skip to content

Clinical trials

Phase 2 Lung Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 2 Clear all

1,069 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200030
200124
200232
200345
200443
200546
200667
200733
200846
200938
201028
201117
201226
201330
201422
201534
201628
201722
201832
201924
202051
202141
202247
202334
202444
202546
202655

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed522
Terminated132
Unknown status125
Recruiting119
Active, not recruiting65
Withdrawn54
Not yet recruiting48
Suspended4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center48
Alliance for Clinical Trials in Oncology38
Memorial Sloan Kettering Cancer Center30
National Cancer Institute (NCI)30
SWOG Cancer Research Network28
SCRI Development Innovations, LLC20
Sun Yat-sen University18
AstraZeneca15
Eli Lilly and Company14
Novartis Pharmaceuticals14

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms1,069
Carcinoma, Non-Small-Cell Lung593
Adenocarcinoma of Lung99
Small Cell Lung Carcinoma87
Breast Neoplasms70
Neoplasm Metastasis51
Adenocarcinoma, Bronchiolo-Alveolar45
Neoplasms43
Brain Neoplasms37
Pancreatic Neoplasms34

Trials

Showing 76 to 100 of 1,069. Each trial links to its page on Pharma Observatory.

969 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.